title: [A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors].
abstract: Cholesterol-lowering drugs include three major pharmacological classes: a) fibrates, b) statines, HMG-CoA reductase inhibitors and c) cholestyramine. The late eighties were characterized by the introduction of HMG-CoA reductase inhibitors in therapeutics. For 12 months (1st January-31 December 1991), a prospective intensive program of pharmacovigilance investigated the occurrence of side effects among the three pharmacological classes of cholesterol-lowering drugs in a specialized unit for prevention of atherosclerosis and dyslipidemia. Among 3,506 out patients who received cholesterol-lowering drugs, 36 side effects were reported (i.e. 1 side effect for 98 out-patients). Most of the side effects were observed with statines (61%). The most frequently observed side effects were gastralgia (19.5%) observed with the three classes of drugs and hepatitis with HMG-CoA reductase inhibitors (8.5%) or fibrates (3%) whereas myopathy (12%) only occurred with statines. The other side effects were cutaneous (14%: eczema, skin rashes) or neuropsychiatric (11%: insomnia...) ones. This study emphasizes the low frequency of severe side effects (myopathy: 1 per 1,000 prescriptions, hepatitis: 1 per 1,000 prescriptions) with cholesterol-lowering drugs in current practice.
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse.
authors.forename: A
authors.initials: A
authors.lastname: Jacquet
authors.forename: M
authors.initials: M
authors.lastname: Colomes
authors.forename: J
authors.initials: J
authors.lastname: Ferrieres
authors.forename: M
authors.initials: M
authors.lastname: Denat
authors.forename: P
authors.initials: P
authors.lastname: Douste-Blazy
authors.forename: J L
authors.initials: JL
authors.lastname: Monstastruc
mesh_terms: D001161:Arteriosclerosis / Q000517:prevention & control; D004346:Drug Information Services; D005602:France; D006801:Humans; D006949:Hyperlipidemias / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D010044:Outpatient Clinics, Hospital; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000960:Hypolipidemic Agents
vernacular_title: Un an de pharmacovigilance prospective et intensive des médicaments hypolipidémiants dans une consultation hospitalière de prévention des facteurs de risque.